Detalhe da pesquisa
1.
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Blood
; 141(7): 756-765, 2023 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36327160
2.
Trial designs and endpoints for immune therapies in multiple myeloma.
Am J Hematol
; 98 Suppl 2: S35-S45, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200130
3.
Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
Ann Hematol
; 100(5): 1261-1266, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33475778
4.
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Hematol Oncol
; 37(1): 35-38, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30209819
5.
In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study.
Biol Blood Marrow Transplant
; 23(7): 1203-1207, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28286198
6.
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Br J Haematol
; 176(3): 440-447, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27859001
7.
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Am J Hematol
; 96(10): E383-E386, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161627
8.
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
Am J Hematol
; 95(2): E51-E54, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31814152
9.
Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.
Curr Probl Cancer
; 50: 101078, 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547609
10.
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Blood Adv
; 8(1): 236-247, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772981
11.
No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma.
Blood Rev
; 57: 100993, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36137842
12.
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
Bone Marrow Transplant
; 58(1): 80-86, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261708
13.
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
Blood Cancer Discov
; 4(6): 440-451, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37769148
14.
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
J Manag Care Spec Pharm
; 29(11): 1205-1218, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776124
15.
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Blood Adv
; 7(6): 1056-1064, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36018226
16.
The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(3): 192-197, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34736880
17.
Strategies to Overcome High-Risk Multiple Myeloma.
Cancer J
; 27(3): 201-204, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34549908
18.
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Ther Adv Hematol
; 12: 2040620721989585, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33796236
19.
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
Ther Adv Hematol
; 12: 2040620720987075, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33613930
20.
Bispecific Antibodies in Multiple Myeloma: Present and Future.
Blood Cancer Discov
; 2(5): 423-433, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34661161